EUVIMEDEUVIMED entdecken
Vergleichsstudie

FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials

Carlotta Antoniotti, Federica Marmorino, Daniele Rossini, Hans Joachim Schmoll, Sara Lonardi, Giuseppe Tonini, Beatrice Borelli, Samanta Cupini, Alexander Stein, Roberto Moretto, Francesca Bergamo, Monica Ronzoni und 7 weitere

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2025.115713 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Carlotta Antoniotti und 18 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medic…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Colorectal Neoplasms, Liver Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBevacizumabColorectal NeoplasmsLiver NeoplasmsHumansLeucovorinProto-Oncogene Proteins B-rafFluorouracilOrganoplatinum CompoundsMutationMiddle AgedMaleFemaleAgedRandomized Controlled Trials as TopicCamptothecinAdultClinical Trials, Phase II as TopicClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

FOLFOXIRI/bevacizumabLiver-only diseaseMetastatic colon cancerRAS and BRAF mutationRight-sided tumour

Substanzen

BevacizumabLeucovorinProto-Oncogene Proteins B-rafFluorouracilOrganoplatinum CompoundsBRAF protein, humanCamptothecin

Autor:innen und Institutionen

  • Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Department of Experimental and Clinical Medicine, University of Florence, Oncology Unit, Careggi University Hospital, Florence, Italy.
  • Department Internal Medicine IV-Hematology-Oncology, Martin-Luther-University, Halle (Saale), Germany.
  • Oncology 1 Unit Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
  • Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma, Italy.
  • Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.

Zitieren

APA

Antoniotti, C., Marmorino, F., Rossini, D., Schmoll, H. J., Lonardi, S., Tonini, G., Borelli, B., Cupini, S., Stein, A., Moretto, R., Bergamo, F., Ronzoni, M., Germani, M. M., Zaniboni, A., Fazio, R., De Grandis, M. C., Ongaro, E., Masi, G., & Cremolini, C. (2025). FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115713

Vancouver

Antoniotti C, Marmorino F, Rossini D, Schmoll HJ, Lonardi S, Tonini G, et al. FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115713

BibTeX
@article{Antoniotti2025,
  author = {Antoniotti, Carlotta and Marmorino, Federica and Rossini, Daniele and Schmoll, Hans Joachim and Lonardi, Sara and Tonini, Giuseppe and Borelli, Beatrice and Cupini, Samanta and Stein, Alexander and Moretto, Roberto and Bergamo, Francesca and Ronzoni, Monica and Germani, Marco Maria and Zaniboni, Alberto and Fazio, Roberta and De Grandis, Maria Caterina and Ongaro, Elena and Masi, Gianluca and Cremolini, Chiara},
  title = {FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2025.115713}
}
Kostenlos starten →